Author Archives: Craig Primack MD FACP



Obesity Medication Update

Posted In: Pharmacology By Craig Primack MD FACP

Anti-obesity medications are FDA approved for patients who have a BMI over 30 and for patients who have a BMI over 27 if they also have a weight related medical condition, like high blood pressure, high cholesterol, type 2 diabetes mellitus or sleep apnea. I also use medication if a patient has obesity based on body fat percentage, which is generally accepted to be >32% for women and >25% for men. [Read more]



Healthy Moms Raise Healthy Children

Posted In: Research By Craig Primack MD FACP

These are results from a prospective cohort of over 16,000 mom-child pairs followed over the years from childhood to adolescence.
This study found that:
Risk was lower in mom’s who maintained:
A normal BMI, Engaged in at least 150 min/week activities, Did not smoke, Consumed alcohol in Moderation. [Read more]



Vivus Pharmaceuticals announces today that Qsymia is now available for Weight Loss
It is the first available weight loss drug in the last 13 years. The weight loss pill is a combination of 2 existing drugs: Phentermine and topiramate. It will be a good tool for weight loss in addition to a plan that includes dietary change, exercise and behavior modification. [Read more]

The new drug, Qsymia, (Vivus) has just been approved by the FDA for Weight Loss and Obesity Treatment. Qsymia is a combination of phentermine and extended release topiramate. The name that has been proposed for the last few years for this drug, Qnexa, has just been changed to Qsymia. [Read more]



In a recent editorial in JAMA (The Journal of the American Medical Association) from the most recent issue, the author found that after reviewing 20 years of outcome studies of patients having bariatric surgery either rou-en-y gastric bypass (the current most common surgery), lap band placement or vertical banded gastroplasty (not commonly performed) that mortality is lessened. [Read more]